{"title":"Is There an Association Between GLP ‐ 1RA Use and Blood Cancer Incidence or Progression?","authors":"Hagop Kantarjian, Ayalew Tefferi","doi":"10.1002/ajh.70552","DOIUrl":"https://doi.org/10.1002/ajh.70552","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"36 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149397351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Franco Locatelli, Michelle L. Schoettler, David Bueno‐Sánchez, Sonali Chaudhury, Jude Fry, Eric Bachman, Min Qin, Cynthia Carrillo‐Infante, Cory Williams, Aviva Krauss, Sarah Lawson, Yoshiyuki Takahashi, Hideki Sano, Daiichirou Hasegawa, Hyoung Jin Kang, Christopher C. Dvorak
{"title":"Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT ‐ TMA : Results of a Phase 3 Trial","authors":"Franco Locatelli, Michelle L. Schoettler, David Bueno‐Sánchez, Sonali Chaudhury, Jude Fry, Eric Bachman, Min Qin, Cynthia Carrillo‐Infante, Cory Williams, Aviva Krauss, Sarah Lawson, Yoshiyuki Takahashi, Hideki Sano, Daiichirou Hasegawa, Hyoung Jin Kang, Christopher C. Dvorak","doi":"10.1002/ajh.70545","DOIUrl":"https://doi.org/10.1002/ajh.70545","url":null,"abstract":"<jats:label/> Hematopoietic stem cell transplantation‐associated thrombotic microangiopathy (HSCT‐TMA) is a rare, life‐threatening complication that can lead to multiorgan failure and death. The ALXN1210‐TMA‐314 global, Phase 3, open‐label, single‐arm trial evaluated ravulizumab, a C5 inhibitor, for treatment of HSCT‐TMA in children (NCT04557735). Eligible participants aged ≥ 28 days to < 18 years had HSCT‐TMA within 12 months from HSCT, which persisted for ≥ 72 h despite initial management. Participants received weight‐based ravulizumab plus best supportive care during the 26‐week treatment period, followed by a 26‐week follow‐up period. The protocol‐defined primary endpoint was complete TMA response during the treatment period. Key secondary endpoints included individual TMA response components (proteinuria, platelets, and lactate dehydrogenase/schistocytes), overall survival (OS), and safety. Of 41 enrolled participants (mean age, 7.6 years; 51.2% female), 28 (68.3%) completed treatment, and 24 (58.5%) completed the study. Through the treatment period, 7 (17.1%) participants achieved complete TMA response, and 22 (53.7%) achieved partial TMA response; 29 (70.7%) participants achieved improvement in ≥ 1 TMA response component. Estimated OS was 92.6% at Day 100, 87.2% at Week 26, and 73.4% at Week 52. During treatment, a low incidence of serious TEAEs was assessed by investigators as related to ravulizumab (3 participants, 7.3%); no new safety signals were identified. No meningococcal infections were reported. In this global Phase 3 trial in children with HSCT‐TMA, ravulizumab treatment resulted in excellent OS and normalization of early laboratory markers of TMA in many patients. Trial Registration NCT04557735","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149397352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mohammed Al Kurnas, Muluken Megiso, Ayalew Tefferi, Xi Zhang, Kebede H Begna
{"title":"Is Bone Marrow Examination Still Required at Diagnosis of Typical Chronic-Phase Chronic Myeloid Leukemia? Evidence From Paired Peripheral Blood and Bone Marrow Cytogenetics.","authors":"Mohammed Al Kurnas, Muluken Megiso, Ayalew Tefferi, Xi Zhang, Kebede H Begna","doi":"10.1002/ajh.70555","DOIUrl":"https://doi.org/10.1002/ajh.70555","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Barbara Gianesin, Rodolfo Russo, Giovanni Battista Ferrero, Filomena Longo, Susanna Barella, Raffaella Origa, Roberto Lisi, Roberta Sciortino, Annamaria Pasanisi, Ilaria Foggetti, Eugenia Mariani, Giovan Battista Ruffo, Valeria Maria Pinto, Gian Luca Forni
{"title":"Longitudinal Kidney Function Trajectories and Their Association With Hemoglobin and Transfusion Phenotype in Adults With β-Thalassemia.","authors":"Barbara Gianesin, Rodolfo Russo, Giovanni Battista Ferrero, Filomena Longo, Susanna Barella, Raffaella Origa, Roberto Lisi, Roberta Sciortino, Annamaria Pasanisi, Ilaria Foggetti, Eugenia Mariani, Giovan Battista Ruffo, Valeria Maria Pinto, Gian Luca Forni","doi":"10.1002/ajh.70554","DOIUrl":"https://doi.org/10.1002/ajh.70554","url":null,"abstract":"<p><p>Renal functional trajectories and their associations with hemoglobin exposure remain incompletely characterized in adults with β-thalassemia. We analyzed 994 adults (806 transfusion-dependent thalassemia [TDT], 188 non-transfusion-dependent thalassemia [NTDT]) followed in the Italian Webthal network for up to 16 years. eGFR was estimated using CKD-EPI 2021 and analyzed using mixed-effects models. Baseline hyperfiltration was present in 22%, but was not associated with significantly faster subsequent eGFR decline. Overall eGFR declined by -1.13 mL/min/1.73 m<sup>2</sup>/year (95% CI, -1.20 to -1.07), with a steeper trajectory in TDT than NTDT. In 877 patients (5529 observations), models incorporating one-year-lagged, time-varying hemoglobin and baseline eGFR showed that hemoglobin-eGFR associations differed across transfusion phenotypes. Among phenoconverted patients, higher lagged hemoglobin was associated with a more negative age-related eGFR slope, persisting in sensitivity analyses accounting for baseline eGFR. Adjustment for hemoglobin did not eliminate phenotype-related differences in slopes. Chelation regimen was not associated with slope differences in the selected long-term monotherapy subgroup. Thus, renal trajectories vary by transfusion phenotype, and their associations with hemoglobin exposure are heterogeneous. Whether declining eGFR reflects attenuation of hyperfiltration or progressive renal injury cannot be established from these observational data.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atsushi Marumo, Arda Durmaz, Christopher Haddad, Aashray Mandala, Felipe de Almeida Sartori, Akram Abushamma, Serhan Unlu, Xiaorong Gu, Zachary Brady, Matteo D'Addona, Kartik Lakhotiya, Luca Guarnera, Masanori Yoshida, Monika M. Toma, Mark D. Orland, Carlos Bravo‐Perez, Carmelo Gurnari, Koichi Takahashi, Tomasz Skorski, Stephan Hutter, Torsten Haferlach, Marcin Wlodarski, Valeria Visconte, Jaroslaw P. Maciejewski
{"title":"Distinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure","authors":"Atsushi Marumo, Arda Durmaz, Christopher Haddad, Aashray Mandala, Felipe de Almeida Sartori, Akram Abushamma, Serhan Unlu, Xiaorong Gu, Zachary Brady, Matteo D'Addona, Kartik Lakhotiya, Luca Guarnera, Masanori Yoshida, Monika M. Toma, Mark D. Orland, Carlos Bravo‐Perez, Carmelo Gurnari, Koichi Takahashi, Tomasz Skorski, Stephan Hutter, Torsten Haferlach, Marcin Wlodarski, Valeria Visconte, Jaroslaw P. Maciejewski","doi":"10.1002/ajh.70542","DOIUrl":"https://doi.org/10.1002/ajh.70542","url":null,"abstract":"<jats:italic>BCOR</jats:italic> and <jats:italic>BCORL1 (BCOR/L1</jats:italic> ) mutations are observed in both myeloid neoplasms (MN) and bone marrow failure syndromes (BMF), but their clinical significance may differ. We analyzed 11 340 patients and identified 418 <jats:italic>BCOR/L1</jats:italic> ‐mutated patients, focusing on differences between MN and BMF. Compared with MN, BMF was associated with younger age, a higher frequency of normal karyotype, a greater proportion of missense mutations, and significantly lower variant allele frequencies (VAFs). We next compared <jats:italic>BCOR/L1</jats:italic> ‐mutated cases with wild‐type cases. In MN, <jats:italic>BCOR/L1</jats:italic> mutations were associated with older age, inferior survival, and a higher number of co‐occurring mutations, whereas in BMF, they were associated with a higher prevalence of PNH clones. Single‐cell DNA sequencing and VAF‐based analysis demonstrated that <jats:italic>BCOR/L1</jats:italic> mutations were usually secondary in MN but primary events in BMF. Longitudinal sequencing revealed that <jats:italic>BCOR/L1</jats:italic> ‐mutant clones often contracted or disappeared over time, even in progression, suggesting limited clonal fitness of <jats:italic>BCOR/L1</jats:italic> mutations themselves; instead, progression was associated with increased mutational burden, particularly in <jats:italic>RUNX1</jats:italic> . Prognostically, <jats:italic>BCOR/L1</jats:italic> mutations were associated with inferior survival in MN, whereas in BMF they were not associated with prognosis and tended to correlate with a favorable response to immunosuppressive therapy. RNA‐sequencing analyses showed reduced BCOR/L1 expression in BMF, and BCOR knockout was associated with reduced HLA class I expression. Our findings suggest that <jats:italic>BCOR/L1</jats:italic> mutations are secondary events in MN and co‐occurring mutations may influence disease progression and prognosis, whereas in BMF they appear to be ancestral events acquired independently of progression to MN, potentially through immune privilege‐related mechanisms.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"13 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149359537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Edward C. C. Wong, Ky Van, Zhen Chen, Caixia Bi, Lance Bare
{"title":"Use of RBC Parameters to Establish Functional Ferritin Cutoffs for the Potential Diagnosis of Iron Deficiency in Adults and Children","authors":"Edward C. C. Wong, Ky Van, Zhen Chen, Caixia Bi, Lance Bare","doi":"10.1002/ajh.70549","DOIUrl":"https://doi.org/10.1002/ajh.70549","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"18 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149359538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Addolorata Truma, Francesco Maria Lo Russo, Giorgio Conte, Ilaria Mancini, Andrea Artoni, Juri Alessandro Giannotta, Barbara Ferrari, Pasquale Agosti, Maria Abbattista, Matteo Gagliardi, Eleonora Piccin, Marco Stroppi, Fabio Maria Triulzi, Flora Peyvandi
{"title":"Cerebral Small Vessel Disease in Immune-Mediated Thrombotic Thrombocytopenic Purpura Patients During the Acute Phase and Disease Remission","authors":"Addolorata Truma, Francesco Maria Lo Russo, Giorgio Conte, Ilaria Mancini, Andrea Artoni, Juri Alessandro Giannotta, Barbara Ferrari, Pasquale Agosti, Maria Abbattista, Matteo Gagliardi, Eleonora Piccin, Marco Stroppi, Fabio Maria Triulzi, Flora Peyvandi","doi":"10.1002/ajh.70506","DOIUrl":"10.1002/ajh.70506","url":null,"abstract":"<p>Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a life-threatening thrombotic microangiopathy characterized by acute neurological manifestations and long-term sequelae related to microvascular brain injury. Cerebral small vessel disease (cSVD), detectable on MRI through lacunes, microbleeds, white matter hyperintensities, and enlarged perivascular spaces, is a risk factor for stroke and cognitive decline, but its prevalence and evolution in iTTP are unknown. We conducted a prospective study of consecutive patients with acute iTTP and age-matched controls to assess the prevalence and one-year progression of cSVD. Brain MRI was performed at enrollment and repeated after 12–18 months in clinical remission. cSVD burden was quantified using a standardized 0–4 score based on four MRI markers. Twenty-five patients (median age 56 years; 60% women) were enrolled. Acute focal ischemic lesions were detected in 13 (52%). cSVD was present in 48% of patients versus 27% of controls, while moderate burden (score ≥ 2) occurred in 24% versus none. Ordinal logistic regression showed an association between iTTP and higher cSVD scores (OR 3.19, 95% CI 1.00–10.14), independent of traditional cardiovascular risk factors. Follow-up MRI was available in 22 patients (88%). In paired analyses, cSVD prevalence increased from 50% to 64%, moderate-to-high burden from 27% to 41%, and six patients (27%) showed score progression. At 1 year, patients had higher odds of greater cSVD burden than controls (age- and sex-adjusted ordinal OR 7.00, 95% CI 1.65–29.74). These findings indicate that cSVD is common during acute iTTP and progresses during the first year despite hematological remission.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3001-3009"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70506","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149019980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Obesity-Related Inflammation Masks Iron Deficiency in US Women","authors":"Sixtus Aguree, Sai Chakrri Tadikonda","doi":"10.1002/ajh.70496","DOIUrl":"10.1002/ajh.70496","url":null,"abstract":"<p>Serum ferritin is the first-line test for iron deficiency because a low value is specific for depleted stores [<span>1</span>]. Ferritin is also an acute-phase reactant: inflammation raises ferritin independently of body iron, so a fixed cutoff misses deficiency when inflammation is present [<span>2</span>]. The World Health Organization now advises that ferritin be read alongside a marker of inflammation [<span>3</span>], and the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project provides a quantitative correction that lowers ferritin according to C-reactive protein (CRP) [<span>4</span>]. This is relevant in the context of obesity, where excess adiposity is associated with chronic low-grade inflammation that raises ferritin while, through hepcidin, also restricting iron supply [<span>5, 6</span>]. Recent papers in this journal and elsewhere set ferritin thresholds (25–30 ng/mL) from the point at which red cell indices begin to fall, found that the thresholds differ by sex and age, and noted that inflammation remains a poorly characterized influence on ferritin [<span>7-10</span>]. We used National Health and Nutrition Examination Survey (NHANES) data to evaluate how much a CRP correction changes iron deficiency prevalence and whether the change is larger at a higher body mass index (BMI). We also asked how the effect differs between women and men, and whether the women it reclassifies show corroborating hematologic evidence of iron restriction.</p><p>We analyzed the NHANES 2017–March 2020 pre-pandemic public-use files, restricting the analysis to non-pregnant adults aged 20 years or older with valid serum ferritin, high-sensitivity CRP, and a recorded BMI [<span>11</span>]. Because serum iron and transferrin saturation vary with meal timing and diurnal rhythm, the primary analysis was restricted to the morning fasting subsample (<i>n</i> = 3623) (mean age 48.4 years, SD: 15.8) with the corresponding survey weights, stratification, and primary sampling units; estimates under the full mobile examination center sample (<i>n</i> = 7644) were closely concordant. Within each sex, we regressed the natural log of ferritin on the natural log of CRP and lowered ln-ferritin by β<sup>CRP</sup> × max(0, lnCRP − lnCRP<sup>ref</sup>), where lnCRP<sup>ref</sup> was the sex-specific tenth percentile of CRP; the maximum operator confines the correction to participants above the reference, so ferritin can only be lowered, never raised. Iron deficiency was defined as ferritin levels below 15 μg/L before and after adjustment. Because adjusted ferritin is by construction no greater than unadjusted ferritin, participants fall into three mutually exclusive groups: iron-replete by both definitions, unmasked by adjustment (replete before, deficient after), and concordantly deficient by both definitions. We compared red cell indices across these groups, together with transferrin saturation and soluble transferrin receptor (sTfR)","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3043-3046"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70496","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148899818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Soluble Transferrin Receptor and the sTfR/Log Ferritin Index May Not Be Better Than Ferritin Alone for Diagnosis of Anemia of Chronic Disease and Iron Deficiency Anemia","authors":"Brett G. Fischer, Jay Canarick","doi":"10.1002/ajh.70513","DOIUrl":"10.1002/ajh.70513","url":null,"abstract":"<p>Noninvasive diagnosis of iron deficiency, especially in the presence of concurrent chronic disease or inflammation, has been a long-standing clinical challenge [<span>1-5</span>]. On that topic, the research article, “Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index,” by Skikne et al. and published in this journal in 2011 [<span>6</span>], has been highly impactful, cited in over 200 publications [<span>7</span>]. Yet, we believe that several of the study's conclusions extend beyond what its data support. Herein, we examine three key conclusions from the study and, using receiver operating characteristic (ROC) curve analysis and flexible cut point selection [<span>8, 9</span>], demonstrate how the published data do not clearly support them.</p><p>\u0000 <i>Conclusion #1:</i> “The sTfR Index is superior to sTfR or ferritin alone [<span>6</span>].”</p><p>It is true that the soluble transferrin receptor (sTfR) Index was shown to be superior to sTfR alone at discriminating between patients with iron deficiency anemia (IDA, with or without concurrent anemia of chronic disease [ACD]) and those with ACD only (without IDA), based on area under the curve (AUC) analysis of ROC curves. However, this analysis did not support the claim that the sTfR Index was superior to ferritin alone because the published article did not include the ROC curve for ferritin or report its AUC. Using the information provided in Table I and the last paragraph of the Results section, we were able to plot three ferritin values on the published ROC graph, which all appear superimposed on the ROC curve for the sTfR Index [<span>6</span>] (Figure 1). Using these points, we were able to construct an approximate ROC curve for ferritin and calculate an AUC of 0.84 (Figure 1), which is similar to the AUC of 0.87 for the sTfR Index and is contained within its 95% confidence interval of 0.81–0.93, indicating that this difference in AUC would not have met the prespecified threshold for statistical significance [<span>6</span>]. While it remains possible that the sTfR Index outperformed high values of ferritin, which would be contained in the portion of the ROC curve for which we did not have access to data, the AUC of 0.84 is probably an underestimate of the true AUC for ferritin in the study due to the oversimplification of plotting just three data points to create the ROC curve (vs. the 145 data points available in the full dataset) [<span>6</span>]. Therefore, we do not believe there is sufficient evidence from the published data to conclude that the sTfR Index was superior to ferritin alone at discriminating between those with and without IDA.</p><p>\u0000 <i>Conclusion #2:</i> “The use of all three parameters in combination more than doubled the detection of IDA, from 41% (ferritin alone) to 92% (ferritin, sTfR, and sTfR Index) [<sp","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3079-3081"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70513","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149085966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ugo Boccadifuoco, Ivan Lerner, Auria Godard, Luc Darnige, Laure Joseph, Wassim El Nemer, Geoffrey Cheminet, Jean-Benoit Arlet
{"title":"The Presence and Percentage of Circulating Nucleated Red Blood Cells Reveal Distinct Characteristics in Adults With Sickle Cell Disease","authors":"Ugo Boccadifuoco, Ivan Lerner, Auria Godard, Luc Darnige, Laure Joseph, Wassim El Nemer, Geoffrey Cheminet, Jean-Benoit Arlet","doi":"10.1002/ajh.70497","DOIUrl":"10.1002/ajh.70497","url":null,"abstract":"<p>Although circulating nucleated red blood cells (cNRBCs) have previously been detected in patients with sickle cell disease (SCD), their prevalence and clinical significance during steady-state disease have not been established. We retrospectively analyzed 270 adults with an SS or Sβ<sup>0</sup>-thalassemia genotype. cNRBCs were counted during steady-state disease. Patients were classified as high cNRBC+ (> 3 per 100 white blood cells (WBCs)), low cNRBC+ (1–3 per 100 WBCs), or cNRBC− (no cNRBCs). cNRBC+ and cNRBC− patients were compared with regard to clinical and laboratory data and in vitro erythroid differentiation from peripheral blood CD34+ cells. cNRBCs were detected in 65.6% of the patients and encompassed all terminal erythroid stages. High cNRBC+ patients were more likely to be receiving hydroxyurea (<i>p</i> = 0.024). cNRBC+ patients exhibited a lower median [IQR] hemoglobin level (8.8 [7.8–10] and 8.4 [7.4–9.4] in the high and low cNRBC+ groups, respectively vs. 9.3 [8.3–9.9] g/dL in the cNRBC− group; <i>p</i> = 0.024). The cNRBC+ percentage was correlated negatively with the reticulocyte and WBC counts and positively with the mean corpuscular volume and the ferritin level. Clinically, a trend toward a greater likelihood of acute chest syndrome was observed in cNRBC+ patients. High cNRBC+ patients' cells exhibited accelerated erythroid differentiation in vitro, suggestive of dyserythropoiesis. cNRBCs constitute a common, easily measurable marker of a distinct hematological phenotype in adult patients with SCD: more severe anemia and signs of dyserythropoiesis. Prospective studies are needed to determine the value of the cNRBC percentage for predicting disease severity and guiding the treatment of dyserythropoiesis.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"2961-2975"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70497","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148915496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}